UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 19 Source: CRO
- €1.1 million turnover
-
-€0.6 million
profit - 0 employees
-
31st Dec 18 Source: CRO
- €36.9 million turnover
-
€25.8 million
profit - 1 employees
- 11 more years available »
Ranking
By Turnover
(€1.1 million)- 964th in Top Companies
- 96th in Health
- 82nd in Pharma
By Employees
(0)- 1026th in Top Companies
- 94th in Health
- 80th in Pharma
-
- 0
- €1.1 million
Employees
- Steve Turley CEO/Managing Director
Latest News
- Jul 28 Facebook shares slide as it warns of slowdown in revenue growth
- Jul 28 Plans for major floating wind farms off Wexford and Wicklow coasts
- Jul 28 European stocks climb after upbeat earnings reports
- Jul 28 Firm ordered to pay €40,000 to woman for discriminatory dismissal
- Jul 28 Kerry Airport reports ‘positive start’ to Ryanair’s Dublin service